Therefore, the inhibition of the glycolytic process or glycolysis-related biosynthetic pathways could reduce MM progression; accordingly, selective inhibition of GLUT1, found highly expressed and associated with worse outcomes of MM patients, antagonized glucose uptake eliciting anti-tumor activity in malignant PCs [20]. This evidence concerns the gene SLC2A1 and Miyoshi myopathy.